Letters and drug alerts sent to healthcare professionals in September 2018
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram adrenaline autoinjectors. MHRA issued alerts and recalls for batches of Olmetec, Mydriasert, Caspofungin, and Imatinib.
All healthcare professionals should be aware of the recent . MHRA has allowed an extension of use beyond the expiry date for certain batches of EpiPen 300 microgram adrenaline autoinjectors.
Patients can continue to use the EpiPen 300 microgram auto-injectors of specified lots safely until the extended use-by date in the table. Further information about batches affected can be found and on the .
In September 2018, MHRA issued the following Alerts and recalls for drugs:
-
Class 4 defect information: Olmetec 20mg Film Coated Tablets (MDR 12-08/18). 3 September 2018. Error on the blister foil of specific batches of Olmetec 20mg Film-Coated Tablets
-
Company-led recall: Mydriasert 0.28mg/5.4mg Ophthalmic Insert. 11 September 2018. Thea Pharmaceuticals are recalling a specific batch of Mydriasert 0.28mg/5.4mg Ophthalmic Insert as it is labelled as being for the French market, rather than the UK market
-
Class 4 defect information: Caspofungin 70mg powder for concentrate for solution for infusion (MDR 11-09/18). 18 September 2018. Error on the patient information leaflet for Caspofungin 70mg powder for concentrate for solution for infusion
-
Company-led Drug Alert: Imatinib 400mg Capsules (3 x 10) PL 36390/0180. 21 September 2018. Error on the Patient Information Leaflet (PIL): the dosage information for the indication CML is incorrect
Article citation: Drug Safety Update volume 12, issue 3: October 2018: 5.